Literature DB >> 27333295

F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death.

William H Gmeiner1, Patricia J Gearhart2, Yves Pommier3, Jun Nakamura4.   

Abstract

Entities:  

Keywords:  DNA repair; DNA topoisomerase I; F10; thymineless death

Mesh：

Substances：

Year:  2016        PMID： 27333295      PMCID： PMC5551924          DOI： 10.2217/fon-2016-0127

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  21 in total

1.  Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Thomas S Dexheimer; Shunichi Takeda; Yves Pommier
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

2.  A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.

Authors:  Zhi-Yong Liao; Olivier Sordet; Hong-Liang Zhang; Glenda Kohlhagen; Smitha Antony; William H Gmeiner; Yves Pommier
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

Review 3.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

4.  A model for the mechanism of human topoisomerase I.

Authors:  L Stewart; M R Redinbo; X Qiu; W G Hol; J J Champoux
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

5.  Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.

Authors:  Timothy S Pardee; Evan Gomes; Jamie Jennings-Gee; David Caudell; William H Gmeiner
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

Review 6.  Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.

Authors:  Maja T Tomicic; Bernd Kaina
Journal:  Biochim Biophys Acta       Date:  2012-09-21

7.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Authors:  Jonathan R Brody; Tomas Hucl; Christina L Costantino; James R Eshleman; Eike Gallmeier; Heng Zhu; Michiel S van der Heijden; Jordan M Winter; Agnieszka K Wikiewicz; Charles J Yeo; Scott E Kern
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

8.  Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes.

Authors:  Marie Regairaz; Yong-Wei Zhang; Haiqing Fu; Keli K Agama; Nalini Tata; Surbhi Agrawal; Mirit I Aladjem; Yves Pommier
Journal:  J Cell Biol       Date:  2011-11-28       Impact factor: 10.539

9.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312

10.  PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.

Authors:  Benu Brata Das; Shar-yin N Huang; Junko Murai; Ishita Rehman; Jean-Christophe Amé; Souvik Sengupta; Subhendu K Das; Papiya Majumdar; Hongliang Zhang; Denis Biard; Hemanta K Majumder; Valérie Schreiber; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2014-02-03       Impact factor: 16.971
View more
  6 in total

1.  All-atom MD indicates ion-dependent behavior of therapeutic DNA polymer.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  Phys Chem Chem Phys       Date:  2017-08-23       Impact factor: 3.676

2.  All-Atom Molecular Dynamics Reveals Mechanism of Zinc Complexation with Therapeutic F10.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  J Phys Chem B       Date:  2016-09-21       Impact factor: 2.991

3.  Floxuridine Homomeric Oligonucleotides "Hitchhike" with Albumin In Situ for Cancer Chemotherapy.

Authors:  Cheng Jin; Hui Zhang; Jianmei Zou; Yan Liu; Lin Zhang; Fengjie Li; Ruowen Wang; Wenjing Xuan; Mao Ye; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2018-06-19       Impact factor: 15.336

4.  AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition.

Authors:  William H Gmeiner; Jonathan R Brody; Alex O Haber; Aditi Jain; Chinnadurai Mani; Avinoam Nevler; Lebaron C Agostini; Talia Golan; Komaraiah Palle; Charles J Yeo
Journal:  Mol Cancer Res       Date:  2021-02-16       Impact factor: 6.333

5.  Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10.

Authors:  William H Gmeiner; Lance D Miller; Jeff W Chou; Anthony Dominijanni; Lysette Mutkus; Frank Marini; Jimmy Ruiz; Travis Dotson; Karl W Thomas; Graham Parks; Christina R Bellinger
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

Review 6.  Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine.

Authors:  William H Gmeiner
Journal:  Molecules       Date:  2020-07-29       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.